Developing the best MATCH for patients through plug & play assembly of novel multispecific biotherapeutics.

numab graphic numab graphic numab graphic numab graphic

Highlights of tech platform & competitive edge

Using a novel, rational process, our proprietary discovery and engineering technology yields multispecific antibody-based therapeutics with tailored pharmacokinetic properties that improve on first generation antibody therapies in terms of potency, stability, effect duration and safety. Alongside our own in-house pipeline programs we have a number of strong discovery and development partnerships with pharma and biotech.

Latest News
December 12, 2019

Numab and 3SBio Group form partnership to develop novel multi-specific antibodies in IO

Numab Therapeutics AG today announced a partnership with 3SBio’s…

Numab Therapeutics AG today announced a partnership with 3SBio’s subsidiary Sunshine Guojian Pharmaceutical focusing on the development and commercialization of a portfolio of novel multi-specific cancer antibodies. As part of the alliance, Sunshine Guojian has invested CHF15M (approximately USD 15.2M) in Numab’s series B financing.
October 15, 2019

Numab appoints Daniel Vasella to Board of Directors

Wädenswil, Switzerland, October 15, 2019 – Numab Therapeutics AG…

Wädenswil, Switzerland, October 15, 2019 – Numab Therapeutics AG today announced that effective October 1 it has appointed former Novartis CEO and Chairman Dr. Daniel Vasella to its Board of Directors.
October 01, 2019

Numab and Eisai enter into global research and option agreement

ZURICH, SWITZERLAND, October 1, 2019 – Numab Therapeutics AG…

ZURICH, SWITZERLAND, October 1, 2019 – Numab Therapeutics AG (Numab) today announced the initiation of a partnership with Eisai, Co., Ltd (Eisai), under a research and option agreement, to discover and develop novel multi-specific antibody immunotherapies for cancer, using Numab’s proprietary MATCH™ platform.
More News
Our websites uses Google Analytics and cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our privacy statement.
Accept